Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.8.0 to v3.8.1. The study details remain unchanged.SummaryDifference0.1%

- Check8 days agoChange DetectedThe ClinicalTrials.gov study record for the pembrolizumab and CC-486 ovarian cancer trial is displayed in place of a 403 error page.SummaryDifference61%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error instead of study details.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide NIH banner announces an update to terminology used across NIH content. The ClinicalTrials.gov site revision changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check43 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check50 days agoChange DetectedThe study page now shows a 403 Forbidden error page with a minimal header and a Home button. This indicates access restrictions rather than changes to the study content.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.